share_log
Reuters ·  Nov 17 09:30
Alnylam Announces Interim Phase 1 Data of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown of Ttr That Is Sustained at Six Months Following a Single Dose
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment